UPR

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

Retrieved on: 
Friday, March 29, 2024
Multiple myeloma, Private placement, Symantec Endpoint Protection, EGFR, CD8, Exercise, Disease, AML, HNSCC, CMV, Patient, Common, Tom Clancy's Ghost Recon, Neoplasm, Immunoglobulin A, Tumor microenvironment, Sale, Bristol Myers Squibb, Form 10-K, Cancer, MHC, PD-L1, Antibody, Interim, Therapy, MTD, Poster, Total, ETB, UPR, Pharmaceutical industry

The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.

Key Points: 
  • The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.
  • Revenues for the fourth quarter of 2023 were $7.0 million, compared to $2.6 million for the same period in 2022.
  • Revenues for the fourth quarter of 2023 were comprised of revenues from collaborative research and development agreements with Bristol-Myers Squibb and grant revenue.
  • For more details on MTEM’s financial results for 2023, refer to Form 10-K filed with the SEC.

Asia-Pacific Recyclable Thermoset Market Report 2022-2031 - Increasing Focus on Sustainability and Bio-Based Renewable Materials

Retrieved on: 
Wednesday, January 31, 2024
Growth, Saturation, Research, Government, Mechanical, Benchmarking, Recycling, Investment, Resin, Electricity, Plastic, Name, Formaldehyde, UPR, Defense

DUBLIN, Jan. 31, 2024 /PRNewswire/ -- The "Asia-Pacific Recyclable Thermoset Market - Analysis and Forecast, 2022-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 31, 2024 /PRNewswire/ -- The "Asia-Pacific Recyclable Thermoset Market - Analysis and Forecast, 2022-2031" report has been added to ResearchAndMarkets.com's offering.
  • In the upcoming years, it is anticipated that the recyclable thermoset market in Asia Pacific will expand rapidly.
  • This is because thermoset recycling technologies are becoming more widely used and there is a growing demand for recycled thermoset materials.
  • Key players in the Asia-Pacific recyclable thermoset market analyzed and profiled in the study involve recyclable thermoset providers.

Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

Retrieved on: 
Thursday, December 14, 2023
Webcast, ID, Safety, Telephone, TSC1, Aadi, Patient, LOS, TSC2, Death, UPR, AADI, ORR, Pneumonitis, Cancer, CMO, Neoplasm, Pharmaceutical industry, Medical imaging, MD

LOS ANGELES, Dec. 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today reported results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial evaluating nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations. 

Key Points: 
  • "Our tumor agnostic PRECISION1 trial is designed to elucidate the impact of nab-sirolimus on cancers expressing inactivating alterations of TSC1 or TSC2, regardless of tumor type.
  • Nine different tumor types were enrolled in the TSC1 arm and 13 tumor types were enrolled in the TSC2 arm.
  • 80 patients are currently enrolled in the PRECISION1 trial, supporting the two-thirds interim analysis expected in the third quarter of 2024.
  • The Aadi management team is hosting a conference call and webcast today at 5:00 pm ET (2:00 pm PT) to discuss the interim results from the PRECISION1 trial.

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Molecule, TILS, Șaeș, Capillary leak syndrome, Arthralgia, Half-life, Biomarker, Therapy, CD4, UPR, PD-1, IL-2, Immunity, Phenotype, Protein, CD8, Pharmacokinetics, Mouse, SITC, Immunotherapy, Plasma, B cell, RDE, NK, Neoplasm, Annual general meeting, Tumor microenvironment, Toxic epidermal necrolysis, Safety, Society, Cancer, Patient, Toxicity, Abstract, Therapeutic index, Fatigue, Pharmaceutical industry, Vaccine

This clinical program is an ongoing, multi-center Phase 1/1b clinical trial of WTX-124, Werewolf’s interleukin 2 (IL-2) INDUKINE molecule, in patients with advanced or metastatic solid tumors.

Key Points: 
  • This clinical program is an ongoing, multi-center Phase 1/1b clinical trial of WTX-124, Werewolf’s interleukin 2 (IL-2) INDUKINE molecule, in patients with advanced or metastatic solid tumors.
  • The preliminary data will be presented today at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, California.
  • The preliminary data include data collected as of October 18, 2023, from 16 heavily pretreated patients from the first four monotherapy dose escalation cohorts (1, 3, 6, 12 mg).
  • The preliminary data established proof of mechanism for WTX-124 and proof of concept for Werewolf’s INDUKINE design.

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023

Retrieved on: 
Friday, November 3, 2023
CR, Neoplasm, Survival, WT1, MTD, DOI, H. Lee Moffitt Cancer Center & Research Institute, OH, Stomach, PDT, Ovarian cancer, EDT, Pembrolizumab, Nucleic acid thermodynamics, Infrared spectroscopy correlation table, DCR, MOS, HPV, Docetaxel, Chair, HNSCC, CPS, Phase, SITC, Cetuximab, Immunotherapy, SD, Clinical trial, Immune system, University Hospitals Cleveland Medical Center, Cancer, ORR, Blood, Methotrexate, EW, Society for Immunotherapy of Cancer, DSD, Safety, Society, Checkmate, Patient, DNA, UPR, Pharmaceutical industry, Vaccine, Communications satellite, Head, Lancet

New clinical data will also be reported from the company’s ongoing Phase 1 trial evaluating its second candidate, CUE-102, for the treatment of Wilms’ Tumor 1 positive (WT1+) recurrent/metastatic cancers.

Key Points: 
  • New clinical data will also be reported from the company’s ongoing Phase 1 trial evaluating its second candidate, CUE-102, for the treatment of Wilms’ Tumor 1 positive (WT1+) recurrent/metastatic cancers.
  • I look forward to evaluating the trial results as they continue to mature and remain highly encouraged by the observations to date.
  • Two patients at the 2mg/kg dose, one with gastric cancer and one with ovarian cancer have demonstrated reduction in tumor burden.
  • Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.

University of Medicine and Health Sciences Presents "Pathways to Practicing Medicine in Puerto Rico"

Retrieved on: 
Tuesday, August 8, 2023
UMHS, Mayo Clinic, University, Student, Southeastern United States, University of Puerto Rico, Medical Sciences Campus, Doctor, Physician, Private practice, Basic research, Hospital, Dream, MD, Patient, UPR, Faculty, ARP, University of Medicine and Health Sciences, Clinical professor, Next Generation, Achievement Medal, Psychiatry, Nursing

NEW YORK,  Aug. 8, 2023 /PRNewswire-PRWeb/ -- The University of Medicine and Health Sciences, (UMHS), a small, mission-driven medical school with a commitment to student support and a legacy of successful residency placements in the United States, Canada, and Puerto Rico, has published the recording of a recent panel discussion, "Pathways to Practicing Medicine in Puerto Rico." The event was hosted by Earl Mainer, UMHS senior associate director of admissions for the Southeastern United States and Puerto Rico, and featured a diverse panel of students, alumni, and practicing physicians to share their experiences, including: Andy Adler, a current UMHS student from Puerto Rico; Dr. Carlos Villanueva Soto, a recent graduate who placed into a highly competitive internal medicine residency at the University of Puerto Rico; Dr. Anelyn Martinez Rodriguez, a 2019 UMHS graduate and current psychiatry resident at San Juan VA Medical Center: and Dr. Eric Adler, a UMHS parent and an esteemed doctor in private practice in Puerto Rico. The panelists addressed common questions from prospective students and their families when evaluating an international medical school – including what it was like to move to St. Kitts, advice for matching into top residency programs, and what it's like to practice medicine in Puerto Rico. A recording of the event has been posted to the UMHS YouTube Live Events & Webinars page.

Key Points: 
  • A recording of the event has been posted to the UMHS YouTube Live Events & Webinars page.
  • "UMHS has been gaining momentum in Puerto Rico as students and their families look for the best options for earning an MD.
  • UMHS was founded by pioneers in medical education to help people get the best training and become medical doctors."
  • Past events include:
    Links to view all past discussions may be found by visiting the UMHS live events and webinars page.

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

Retrieved on: 
Monday, June 5, 2023
KRAS, Communication, MYC, Probability, CRC, DCR, SOS1, Clinical trial, Encorafenib, DDI, Trae tha Truth, BRAF, Research, SHP2, CNS, Cetuximab, RAS, Patient, EGFR, Colorectal cancer, ERK, SAN, HNSCC, HPV, UPR, EC, CPRS, Resuscitation, Safety, Pharmaceutical industry

SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced promising preliminary Phase 1b data for ERK inhibitor ERAS-007 in patients with metastatic BRAF V600E-mutated (BRAFm) colorectal cancer (CRC) and provided a portfolio update. Erasca will host a virtual investor event to discuss these updates today at 4:30 PM ET. To register for the event, please click here.

Key Points: 
  • Erasca will host a virtual investor event to discuss these updates today at 4:30 PM ET.
  • To register for the event, please click here .
  • “We are pleased that the early ERAS-007 clinical data continue to reinforce its potential to become a backbone for combination therapy,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder.
  • “Moreover, through our signal-seeking trials, we have tested three biological hypotheses: preventing in-pathway resistance, reversing in-pathway resistance, and targeting adjacent pathways.

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Retrieved on: 
Sunday, June 4, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Puma Biotechnology, Translational Genomics Research Institute, MYC, City of Hope, TP53, Texas Oncology, Unfolded protein response, Progression-free survival, Metastasis, HER2, Neoplasm, Paclitaxel, Biomarker, RNA, PFS, Trial of the century, AKT1, ASCO, HR, City, American Society of Clinical Oncology, Patient, Breast cancer, MBC, Baylor University Medical Center, Annual general meeting, Puma, Cancer, UPR, AURKA, Poster, CDT, Research, Phase, Abstract, Woman, Gene, Society, JAMA Network Open, CDH1, Disease, Pharmaceutical industry, Vaccine, Medical imaging, PIK3CA

(Jama Network Open, April 2021) and showed that the addition of alisertib to paclitaxel improved progression-free survival (PFS) among enrolled patients compared with paclitaxel alone (HR, 0.56; 95%CI, 0.37-0.84; P = .005).

Key Points: 
  • (Jama Network Open, April 2021) and showed that the addition of alisertib to paclitaxel improved progression-free survival (PFS) among enrolled patients compared with paclitaxel alone (HR, 0.56; 95%CI, 0.37-0.84; P = .005).
  • No mutations were significantly associated with response or resistance to alisertib plus paclitaxel, including those in PIK3CA, TP53, AKT1, HER2, and CDH1.
  • Increased MYC RNA expression was not observed in patients who did not appear to benefit from alisertib plus paclitaxel.
  • This biomarker analysis will be very helpful to the design of the future trials of alisertib that we are planning in hormone receptor positive HER2-negative breast cancer.”

UAE Ministry of Interior Launches Pioneering Strategy to Use AI to Protect Children Online

Retrieved on: 
Friday, May 19, 2023
United Nations Interregional Crime and Justice Research Institute, Partnership, United Nations, WeProtect, United Nations Human Rights Council, UNICRI, MOI, Palace of Nations, Diplomatic mission, Child protection, CSAM, Ministry, Working Group, Ministry of Interior (Saudi Arabia), Robotics, Machine learning, Child, FBI, Interior, UPR, AI, Universal Periodic Review, Environment, Mental health, United Arab Emirates, Safety, Tutoring, Drug

The UAE Ministry of Interior launches new Child Protection Strategy to tackle the surge of online child abuse at the United Nations Human Rights Council's 43rd Session of the Universal Periodic Review.

Key Points: 
  • The UAE Ministry of Interior launches new Child Protection Strategy to tackle the surge of online child abuse at the United Nations Human Rights Council's 43rd Session of the Universal Periodic Review.
  • UAE intends to promote a holistic approach for child protection, which empowers children, upholds values and creates a safe and cohesive environment online.
  • Speaking at the launch event, Irakli Beridze, Head of the Centre for AI and Robotics at UNICRI, highlighted the use of AI as the most progressive way to safeguard children online and endorsed UAE's strategy.
  • The newly unveiled Child Protection Strategy builds on the UAE MOI's global leadership advocacy, capacity-building, operations and policy-making relevant for improving the protection of children online.

IMPAC: International coalition of 53 NGOs praises the leadership of Sheikh Mohammed bin Zayed in promoting and protecting human rights in the UAE.

Retrieved on: 
Wednesday, May 3, 2023
IMPAC, United Nations, Education, United Nations Human Rights Council, Women's rights, Supreme Council, United, UN, Supreme Council for Women, UPR, Climate, Racism, Universal Periodic Review, Empowerment, United Arab Emirates, International Movement ATD Fourth World, Drug, Coexistence, Woman

The coalition also organized an international symposium in Geneva, parallel to the 52nd session of the Human Rights Council, which discussed the existing and future challenges for human rights in the UAE.

Key Points: 
  • The coalition also organized an international symposium in Geneva, parallel to the 52nd session of the Human Rights Council, which discussed the existing and future challenges for human rights in the UAE.
  • A symposium organized by a coalition of human rights organizations discussed the recent progress made in human rights in the UAE.
  • The symposium was attended by experts in the field of human rights and representatives from various countries.
  • The final statement paid tribute to the global impact of the President of the UAE, Sheikh Mohamed bin Zayed, in furthering peace, promoting tolerance and human coexistence, developing greater capacity for human fraternity.